Midodrine
Lung Neoplasms
Yonsei UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 73/ 100
Competitive context
47 Active assets in the Lung Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Nanfang Hospital, Southern Medical University | Phase 4 | BB |
Icotinib Fuda Cancer Hospital, Guangzhou | Phase 4 | BB |
Cyclophosphamide Pfizer | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Nanfang Hospital, Southern Medical University | Phase 3 | B |
Pembrolizumab Sarah Goldberg | Phase 3 | B |
View all 50 →
Same molecule, other indications
Midodrine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →